Manufacturing method

Details for Australian Patent Application No. 2005235787 (hide)

Owner Hydrogen Solar Ltd

Inventors Augustynski, Jan; Solarska, Renata; Ulmann, Martine

Agent Adams Pluck

Pub. Number AU-A-2005235787

PCT Pub. Number WO2005/103329

Priority 0408887.8 21.04.04 GB

Filing date 21 April 2005

Wipo publication date 3 November 2005

International Classifications

C23C 18/12 (2006.01) Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coating

C03C 17/25 (2006.01) Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating - by deposition from the liquid phase

C03C 17/34 (2006.01) Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating - with at least two coatings having different compositions

C25B 1/00 (2006.01) Electrolytic production of inorganic compounds or non-metals

Event Publications

7 December 2006 PCT application entered the National Phase

  PCT publication WO2005/103329 Priority application(s): WO2005/103329

11 September 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005235789-Convergent synthesis for kahalalide compounds

2005235786-Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors